2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Cdc42-binding kinase
  5. Cdc42-binding kinase Inhibitor

Cdc42-binding kinase Inhibitor

Cdc42-binding kinase Isoform Comparison

Cdc42-binding kinase Inhibitors (3):

Cat. No. Product Name Effect Purity
  • HY-111424
    BDP9066
    		Inhibitor 98.36%
    BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
  • HY-111424A
    (R)-BDP9066
    		Inhibitor 98.49%
    (R)-BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 blocks cancer cell invasion. (R)-BDP9066 has the potential for the research of proliferative diseases, such as cancer.
  • HY-111423
    BDP8900
    		Inhibitor
    BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ). BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells.